The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd‐Catalyzed Reactions

Advanced Synthesis and Catalysis - Tập 346 Số 8 - Trang 889-900 - 2004
Christine E. Garrett1, Kapa Prasad1
1Process Research and Development, Novartis Institute for Biomedical Research, One Health Plaza, East Hanover, NJ 07936, USA, Fax: (+1)‐973‐781‐2188

Tóm tắt

AbstractThe use of palladium‐derived catalysts in the synthesis of fine chemicals, pharmaceutical intermediates and active pharmaceutical ingredients (APIs) has become quite common in the last few decades. The number of palladium‐catalyzed synthetic reactions (both achiral and chiral) available to chemists has provided access to more complex structures in fewer steps and with less waste, due to the catalytic nature of many of the methods. An unfortunate side effect of using palladium is the potential for palladium‐containing impurities to remain in the desired compound after isolation. This is an especially significant problem for the pharmaceutical industry since there is a low limit for heavy metal impurities allowed in the drug substance. Therefore, various methods of removing palladium impurities from organic compounds of pharmaceutical interest have been developed. This review will provide a survey of the published methods but is not meant to be inclusive of all published material in this area of research.

Từ khóa


Tài liệu tham khảo

Heck R. F., 1985, Palladium Reagents in Organic Syntheses

Tsuji J., 1995, Palladium Reagents and Catalysts

10.1002/0471212466

2002, Environmental Health Criteria for Palladium

2002, Note for Guidance on Specification Limits for Residues of Metal Catalysts

http://www.emea.eu.int.

Which will hydrolyze under the test conditions to generate H2Sin situ.

1995, USP Analysis of Heavy Metals, US Pharmacopeia – National Formulary

1992, Principles of Instrumental Analysis

10.1081/SCC-120003154

10.1081/CR-100107480

U. Beutler R. Schneitter P. Schorter (Novartis) personal communication.

10.1021/op970107f

Although this treatment was quite effective the solvent system can affect whether the TMT‐Pd complex is insoluble or not which would change the efficiency with which it can be removed.

10.1246/cl.2000.1218

Argonaut technical note # 515 2003 MP‐TMT.

10.1021/op0255682

D. Xu M. Oberholzer A. Tedesco (Novartis) personal communication.

10.1002/1615-4169(200107)343:5<461::AID-ADSC461>3.0.CO;2-#

Biotage Inc. technical reference document.

10.1039/a802593b

Johnson Matthey technical document.

www.silicycle.com/angl/funct.htm.

SigmaAldrich on‐line technical documentation.

10.1021/op034072x

J. Slade H. Liu (Novartis) personal communication.

10.1021/op025615q

10.1021/jo00100a048

M.Villa V.Cannata A.Rosi P.Allegrini World PatentWO98/51646 1998.

P.Giguere S.Iera M.Bernatchez G.Barreca G.Castaldi V.Cannata World PatentWO 96/40684 1996.

This report also indicates that theN‐acetylcysteine (or cysteine which appears less effective at removing the palladium) can be added as a solid to the organic phase stirred and the resulting solids which contain a significant amount of the palladium can be filtered off.

10.1002/adsc.200390062

10.1021/jo0205614

Maryanoff C. A., 1988, Catalysis of Organic Reactions

Thông tin
Thông tin xuất bản

Advanced Synthesis and Catalysis

Tập 346 Số 8

889-900

Thông tin tác giả